UK, with high hopes of helping Covid-19 patients stop developing serious illness.
The new treatment involves inhaling a protein called Interferon Beta, which the body produces in infection.
The hope is that this will stimulate the immune system and the cells will be prepared to fight viruses.
Initial results from the trials showed that treatment reduced by nearly 80 percent the chances of patients in hospital with Covid-19 developing severe diseases.
Results from phase two trials of around 100 patients last year also indicated “very significant” reductions in breathlessness, while the average time patients spent in hospital was reduced by a third down from an average of nine days to six days.